Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study

INTRODUCTION: Rilpivirine (RPV) is a new once-daily, non-nucleoside, reverse transcriptase inhibitor (NNRTI). In treatment-naïve patients, RPV has shown non-inferior antiviral activity to efavirenz but data in treatment-experienced patients are more limited. We assessed the efficacy and safety of RP...

Descripción completa

Detalles Bibliográficos
Autores principales: Gazaignes, Sandrine, Resche-Rigon, Matthieu, Yang, Chloe, Gatey, Caroline, Munier, Anne-Lise, Desseaux, Kristell, Rozenbaum, Willy, Molina, Jean-Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P264
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225255/
https://www.ncbi.nlm.nih.gov/pubmed/25397540
http://dx.doi.org/10.7448/IAS.17.4.19796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225255/
https://www.ncbi.nlm.nih.gov/pubmed/25397540
http://dx.doi.org/10.7448/IAS.17.4.19796

Ejemplares similares